{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:30:45Z","timestamp":1789831845144,"version":"4.0.1"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.atherosclerosis.2023.117213","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T10:08:14Z","timestamp":1691057294000},"page":"117213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["HDL abnormalities in type 2 diabetes: Clinical implications"],"prefix":"10.1016","volume":"394","author":[{"given":"Alexandro J.","family":"Martagon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Zubir\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Gonz\u00e1lez-Arellanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Praget-Bracamontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Adri\u00e1n","family":"Rivera-Alc\u00e1ntara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-0241","authenticated-orcid":false,"given":"Carlos A.","family":"Aguilar-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9785","key":"10.1016\/j.atherosclerosis.2023.117213_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2\u00b77 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/17843286.2019.1702823","article-title":"Evolving concepts on the management of dyslipidaemia","volume":"75","author":"Descamps","year":"2020","journal-title":"Acta Clin. Belg."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib3","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American heart association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation [Internet]"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2023.117213_bib4","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","article-title":"High-density lipoprotein revisited: biological functions and clinical relevance","volume":"44","author":"von Eckardstein","year":"2023","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MOL.0b013e32833bcdc1","article-title":"Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities","volume":"21","author":"Kontush","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nsmb.2028","article-title":"Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma","volume":"18","author":"Huang","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2023.117213_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0022-2275(20)38761-7","article-title":"On computer-assisted analysis of biological sequences: proline punctuation, consensus sequences, and apolipoprotein repeats","volume":"27","author":"Boguski","year":"1986","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0022-2275(20)38532-1","article-title":"The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution","volume":"29","author":"Li","year":"1988","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib9","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0006-291X(72)90776-0","article-title":"A protein cofactor of lecithin:Cholesterol acyltransferase","volume":"46","author":"Fielding","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib10","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1021\/bi00733a026","article-title":"Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources","volume":"12","author":"Havel","year":"1973","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/iub.1314","article-title":"Apolipoprotein E isoforms and lipoprotein metabolism: apolipoprotein E isoforms and lipoprotein metabolism","volume":"66","author":"Phillips","year":"2014","journal-title":"IUBMB Life"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/biom13030497","article-title":"Altered distribution of unesterified cholesterol among lipoprotein subfractions of patients with diabetes mellitus type 2","volume":"13","author":"Kolb","year":"2023","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117213_bib13","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/01.ATV.0000038485.94020.7F","article-title":"Metabolism of ApoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits","volume":"22","author":"Kee","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2023.117213_bib14","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1074\/jbc.272.7.3953","article-title":"Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion","volume":"272","author":"Rye","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/bj3130275","article-title":"The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion","volume":"313","author":"Lusa","year":"1996","journal-title":"Biochem. J."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2023.117213_bib16","doi-asserted-by":"crossref","first-page":"8864","DOI":"10.1074\/jbc.M117.781963","article-title":"Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester","volume":"292","author":"Gillard","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2023.117213_bib17","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1194\/jlr.R035725","article-title":"Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond","volume":"54","author":"Shah","year":"2013","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117213_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/eurjpc\/zwac015","article-title":"New evidences on the association between high-density lipoprotein cholesterol and cardiovascular risk: a never ending research story","volume":"29","author":"Fogacci","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2023.117213_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.RES.0000146031.94850.5f","article-title":"Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential","volume":"95","author":"Ribas","year":"2004","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117213_bib20","first-page":"327","article-title":"\u03a4he role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma","volume":"1791","author":"Tellis","year":"2009","journal-title":"Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2023.117213_bib21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/89986","article-title":"High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase","volume":"7","author":"Yuhanna","year":"2001","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI200418004","article-title":"HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3","volume":"113","author":"Nofer","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117213_bib23","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1074\/jbc.M211394200","article-title":"High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases","volume":"278","author":"Mineo","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117213_bib24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1152\/jappl.1992.73.5.1925","article-title":"Novel myosin isoform in nuclear chain fibers of rat muscle spindles produced in response to endurance swimming","volume":"73","author":"Yoshimura","year":"1992","journal-title":"J. Appl. Physiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.ATV.18.9.1450","article-title":"Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells","volume":"18","author":"Ashby","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117213_bib26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2023.117213_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218533","article-title":"Role of HDL function and LDL atherogenicity on cardiovascular risk: a comprehensive examination. Feng YM, editor","volume":"14","author":"Hern\u00e1ez","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2023.117213_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0002-9149(02)03383-0","article-title":"High-density lipoprotein subpopulations in pathologic conditions","volume":"91","author":"Asztalos","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"15","key":"10.1016\/j.atherosclerosis.2023.117213_bib29","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","article-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport","volume":"125","author":"Rosenson","year":"2012","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11886-014-0512-5","article-title":"Role of HDL in those with diabetes","volume":"16","author":"Santos-Gallego","year":"2014","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib31","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2147\/DMSO.S383234","article-title":"The correlation between angiopoietin-like 3 and metabolic markers of some lipid and glucose in type 2 diabetes mellitus patients at the first diagnosis","volume":"15","author":"Hoang Thi","year":"2022","journal-title":"Diabetes, Metab. Syndrome Obes. Targets Ther."},{"issue":"590","key":"10.1016\/j.atherosclerosis.2023.117213_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0602","article-title":"Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial","volume":"13","author":"Le Lay","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117213_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/jc.2017-01551","article-title":"Glycation reduces the stability of ApoAI and increases HDL dysfunction in diet-controlled type 2 diabetes","volume":"103","author":"Kashyap","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9841","key":"10.1016\/j.atherosclerosis.2023.117213_bib34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131491","article-title":"Structure-function relationships of HDL in diabetes and coronary heart disease","volume":"5","author":"Cardner","year":"2020","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2023.117213_bib36","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/erc.11.182","article-title":"HDL dysfunction in diabetes: causes and possible treatments","volume":"10","author":"Farbstein","year":"2012","journal-title":"Expert Rev. Cardiovasc Ther."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117213_bib38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCULATIONAHA.113.002671","article-title":"High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy","volume":"128","author":"Mora","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2023.117213_bib39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2217\/pme-2018-0046","article-title":"Oxidized-LDL is a useful marker for predicting the very early coronary artery disease and cardiovascular outcomes","volume":"15","author":"Zhao","year":"2018","journal-title":"Pers. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117213_bib40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"The multiple risk factor intervention trial research group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12944-017-0594-3","article-title":"The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk","volume":"16","author":"Femlak","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bph.12174","article-title":"HDL and endothelial protection: HDL and endothelial protection","volume":"169","author":"Tran-Dinh","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117213_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.atherosclerosis.2010.12.026","article-title":"Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI","volume":"215","author":"Brodde","year":"2011","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2023.117213_bib44","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.21037\/apm-22-437","article-title":"Systematic review and meta-analysis of the related factors for diabetic retinopathy","volume":"11","author":"Xuan","year":"2022","journal-title":"Ann. Palliat. Med."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117213_bib45","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2337\/dc12-0306","article-title":"Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy","volume":"35","author":"Morton","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbacli.2015.01.005","article-title":"High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk","volume":"3","author":"Hafiane","year":"2015","journal-title":"BBA Clin."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117213_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0021-9150(02)00361-1","article-title":"High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study","volume":"166","author":"Yu","year":"2003","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib48","article-title":"High density lipoprotein as a biomarker, potential therapeutic target and therapy","volume":"5","author":"Shirin","year":"2021","journal-title":"Ann. Heart [Internet]"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117213_bib49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1373\/clinchem.2007.101923","article-title":"Laboratory assessment of HDL heterogeneity and function","volume":"54","author":"Movva","year":"2008","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib50","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/157016112800812755","article-title":"Proteomics investigations of HDL: challenges and promise","volume":"10","author":"Vaisar","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117213_bib51","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0006-2952(99)00263-4","article-title":"Reaction of metformin with dicarbonyl compounds. possible implication in the inhibition of advanced glycation end product formation","volume":"58","author":"Ruggiero-Lopez","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00129784-200202010-00003","article-title":"Management of Co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones","volume":"2","author":"Florkowski","year":"2002","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1258\/acb.2012.012019","article-title":"Pioglitazone protects HDL 2&3 against oxidation in overweight and obese men","volume":"50","author":"Mceneny","year":"2013","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117213_bib54","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib55","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s001250050045","article-title":"Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes","volume":"43","author":"Raskin","year":"2000","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MOL.0000000000000751","article-title":"Lipid effects of sodium-glucose cotransporter 2 inhibitors","volume":"32","author":"Lazarte","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib57","series-title":"GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis","first-page":"1","author":"Rezaei","year":"2021"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib58","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1185\/03007995.2014.921608","article-title":"The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis","volume":"30","author":"Dai","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2023.117213_bib59","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/jcph.1431","article-title":"Effects of sitagliptin on lipid profile in patients with type 2 diabetes mellitus after 7 Years of therapy","volume":"59","author":"Derosa","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.phrs.2014.02.009","article-title":"Cardiovascular effects of statins, beyond lipid-lowering properties","volume":"88","author":"Mihos","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"9607","key":"10.1016\/j.atherosclerosis.2023.117213_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib62","doi-asserted-by":"crossref","first-page":"708","DOI":"10.5551\/jat.17210","article-title":"Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients","volume":"20","author":"Miyamoto-Sasaki","year":"2013","journal-title":"J. Atherosclerosis Thromb."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117213_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/2040622310389227","article-title":"Pitavastatin: finding its place in therapy","volume":"2","author":"Ose","year":"2011","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib64","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2018.08.027","article-title":"Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes","volume":"277","author":"Mu\u00f1oz-Hernandez","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib65","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40261-015-0372-9","article-title":"Association between paradoxical HDL cholesterol decrease and risk of major adverse cardiovascular events in patients initiated on statin treatment in a primary care setting","volume":"36","author":"Hasvold","year":"2016","journal-title":"Clin. Drug Invest."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2023.117213_bib66","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib67","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1185\/030079904X2321","article-title":"Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome","volume":"20","author":"Simons","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"10106","key":"10.1016\/j.atherosclerosis.2023.117213_bib68","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib69","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.25641","article-title":"The use of monoclonal antibody-based proprotein convertase subtilisin-kexin type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia","author":"Parikh","year":"2022","journal-title":"Cureus [Internet]"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2023.117213_bib70","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"10.1016\/j.atherosclerosis.2023.117213_bib72","article-title":"Effectiveness of niacin supplementation for patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"99","author":"Xiang","year":"2020","journal-title":"Medicine (Baltim.)"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117213_bib73","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCULATIONAHA.111.018259","article-title":"Effect of torcetrapib on glucose, insulin, and hemoglobin A 1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial","volume":"124","author":"Barter","year":"2011","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2023.117213_bib74","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib75","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/cells10040850","article-title":"High density lipoproteins and diabetes","volume":"10","author":"Cochran","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib76","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2023.117213_bib77","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6341","key":"10.1016\/j.atherosclerosis.2023.117213_bib78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"issue":"1\u20133","key":"10.1016\/j.atherosclerosis.2023.117213_bib79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0021-9150(85)90063-2","article-title":"Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns","volume":"58","author":"Franceschini","year":"1985","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib80","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jamacardio.2018.2112","article-title":"Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial","volume":"3","author":"Nicholls","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib81","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2017.12.031","article-title":"HDL acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction","volume":"478","author":"Soares","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2023.117213_bib82","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary AtherosclerosisA randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117213_bib83","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/ATVBAHA.113.301981","article-title":"Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux","volume":"33","author":"Diditchenko","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2023.117213_bib84","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002171","article-title":"Infusion of reconstituted high\u2010density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial","volume":"4","author":"Tricoci","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.117213_bib85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ahj.2020.10.052","volume":"231","author":"Gibson","year":"2021","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.10.018","article-title":"CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice","volume":"232","author":"Tardy","year":"2014","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2023.117213_bib87","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.7326\/L20-1300","article-title":"Administration of the high-density lipoprotein mimetic CER-001 for inherited lecithin\u2013cholesterol acyltransferase deficiency","volume":"174","author":"Faguer","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117213_bib88","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/biomedicines10040754","article-title":"First recombinant high-density lipoprotein particles administration in a severe ICU COVID-19 patient, a multi-omics exploratory investigation","volume":"10","author":"Tanaka","year":"2022","journal-title":"Biomedicines"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2023.117213_bib89","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014572","article-title":"MEDI6012: recombinant human lecithin cholesterol acyltransferase, high\u2010density lipoprotein, and low\u2010density lipoprotein receptor\u2013mediated reverse cholesterol transport","volume":"10","author":"George","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1476-511X-10-17","article-title":"The impact of plasma triglyceride and apolipoproteins concentrations on high-density lipoprotein subclasses distribution","volume":"10","author":"Tian","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib91","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1476-511X-11-54","article-title":"High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes","volume":"11","author":"Tian","year":"2012","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib92","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1476-511X-9-118","article-title":"The relationship between high density lipoprotein subclass profile and plasma lipids concentrations","volume":"9","author":"Tian","year":"2010","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117213_bib93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11745-008-3251-9","article-title":"Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome","volume":"44","author":"Lagos","year":"2009","journal-title":"Lipids"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2023.117213_bib94","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","article-title":"Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial","volume":"25","author":"Asztalos","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117213_bib95","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/01.ATV.0000146325.93749.a8","article-title":"High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the framingham offspring study","volume":"24","author":"Asztalos","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2023.117213_bib96","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/01.ATV.20.12.2670","article-title":"Distribution of ApoA-I\u2013containing HDL subpopulations in patients with coronary heart disease","volume":"20","author":"Asztalos","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117213_bib97","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2023.117213_bib98","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1373\/clinchem.2017.275636","article-title":"High-density lipoprotein subclasses, coronary artery disease, and cardiovascular mortality","volume":"63","author":"Silbernagel","year":"2017","journal-title":"Clin. Chem."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023051274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023051274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:57:17Z","timestamp":1723737437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023051274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":98,"alternative-id":["S0021915023051274"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117213","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDL abnormalities in type 2 diabetes: Clinical implications","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117213"}}